Login
Companies $JAZZ
$239.77 -$1.78 (0.74%) Live
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc

jazzpharma.com

What Do They Do?

Sells medicines for rare sleep disorders, epilepsy and cancers to patients with those conditions.

How Do They Make Money?

Jazz sells medicines to specialty pharmacies, distributors and hospitals, with product sales tied to delivery. It also earns royalties on licensed medicine sales and receives upfront and milestone payments for licensing rights.

revenue
SegmentShareRevenue
Product sales, net
Sold outright

94%
FY2022: 100%
High-sodium oxybate AG royalty revenue
Licensed
5.0%
FY2022: 0.0%
Other royalty and contract revenues
Licensed
0.8%
FY2022: 0.5%

Who Are Their Customers?

U.S. oxybate and Modeyso prescriptions go through certified specialty pharmacies that ship directly to patients; other medicines are sold to specialty pharmacies, distributors and hospitals. Outside the U.S., sales run through wholesalers and distributors, with some European sales made directly to hospitals and local wholesalers.

Customers above 10% of revenue, FY2025
of revenue from three customers (42%, 11%, 10%)
FY2024: 63% from three customers

Do Revenues Turn Into Profits?

Not on paper. It lost $356.1M in FY2025, but brought in more cash than it spent: $1.3B of free cash flow.

Operating income, FY2025
−10% of revenue
▼ Turned to a loss vs FY2024 ($716.6M, 18%)
Net income, FY2025
−8% of revenue
▼ Turned to a loss vs FY2024 ($560.1M, 14%)
Free cash flow, FY2025
30% of revenue
▼ −4% vs FY2024 ($1.4B, 33%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +10%
vs $1.1B in Q3 FY2025
Net income
▼ Turned to a loss
vs $251.4M in Q3 FY2025
Product sales, net share of revenue vs 94.5% in Q3 FY2025
  • Aug 25, 2026 FDA approved Ziihera combinations as initial treatment for gastroesophageal cancer The approval covers Ziihera with chemotherapy, with or without Tevimbra, for adults with HER2-positive disease.
  • Aug 10, 2026 Agreed to acquire Actio Biosciences
  • Aug 3, 2026 Raised revenue guidance The 2026 revenue guidance range rose to $4.60 - $4.75 billion.

Growing. Revenue grew 38% in 4 years, from $3.1B in FY2021 to $4.3B in FY2025, about 8% a year.

Portfolio additions Jazz added Ziihera and Modeyso to its commercialized cancer medicines, alongside its earlier treatments for sleep disorders, epilepsy and cancer.

Revenue over time
Product sales, net High-sodium oxybate AG royalty revenue Other royalty and contract revenues
$5B$2.5B$0

Who Do They Compete With?

Competes with Alkermes, Avadel, Amneal, Ascent, Hikma, Lupin, Teva, Granules, Harmony Biosciences, Axsome, Takeda, Merck &, Eisai, Centessa Pharmaceuticals, Zogenix, UCB, Marinus Pharmaceuticals, Ovid Therapeutics, Praxis Precision Medicines, and Bright Minds Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support